https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-214025&utm_campaign=recommended-articles-pi
Cadonilimab is under clinical development by Akeso and currently in Phase II for Pancreatic Ductal Adenocarcinoma.
cadonilimabakesopancreaticadenocarcinomalikelihood
https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/
Cadonilimab is under clinical development by Akeso and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).
squamous cell carcinomacadonilimabakesoheadneck
https://www.biospace.com/akeso-announces-launch-of-u-s-investigator-initiated-study-of-cadonilimab-pd-1-ctla-4-bispecific-antibody
Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's...
investigator initiated studyakesoannounceslaunch
https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-squamous-non-small-cell-lung-carcinoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-280693&utm_campaign=recommended-articles-pi
Cadonilimab is under clinical development by Akeso and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma.
small celllung carcinomacadonilimabakesosquamous